EDBI
VC Fund
Singapore, Singapore
EDBI is a VC fund in Singapore focused on Biotechnology and Software. Investing since 1991, EDBI is a Singapore-based global investor in select high-growth technology sectors ranging from Information and Communication Technology (ICT), Emerging Technology (ET), Healthcare (HC), and other strategic industries. As a value-creating investor, EDBI assists companies to achieve their ambitious goals by leveraging theirbroad network, resources, and expertise. With their patient capital, EDBI supports companies seeking to grow in Asia and globally through Singapore.
- Total investments:
- 195
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries EDBI invests in
Stages EDBI invests in
Countries EDBI invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series B
- $20M–$170M
- Series C
- $12M–$275M
- Series D
- $17M–$400M
Investment Focus
Industry
- Biotechnology 37 (19%)
- Software 34 (17%)
- Health Care 32 (16%)
- Artificial Intelligence 19 (10%)
- Medical 16 (8%)
Stage
- Series C 41 (21%)
- Series B 30 (15%)
- Series D 27 (14%)
- Series A 22 (11%)
- Funding Round 22 (11%)
Country
- United States 81 (42%)
- Singapore 43 (22%)
- India 4 (2%)
- China 3 (2%)
- United Kingdom 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chu Swee Yeok
CEO and President
|
CEO and President | Total investments: 25 | Find email | |
Jolene Ooi
Senior Principal
|
Senior Principal | Total investments: 2 | Find email | |
|
Lawrence Low
Senior Vice President, Investments
|
Senior Vice President, Investments | Total investments: 2 | Find email | |
Paul Ng
Managing Partner; Chief Executive Officer
|
Managing Partner; Chief Executive Officer | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Horizon3.ai
|
Horizon3.ai's mission is to help you find and fix your attack vectors before criminals exploit them. NodeZero, our automated penetration testing solution, enables organizations to continuously assess the security posture of their enterprise, including external, identity, on-prem, IoT, and cloud attack surfaces. Like APTs, ransomware, andother threat actors, our algorithms discover and fingerprint your attack surface, identifying the ways exploitable vulnerabilities, misconfigurations, harvested credentials, and dangerous product defaults can be chained together to facilitate a compromise. NodeZero is a true self-service SaaS offering that is safe to run in production and requires no persistent or credentialed agents. You will see your enterprise through the eyes of the attacker, identify your ineffective security controls, and ensure your limited resources are spent fixing problems that can actually be exploited. Founded in 2019 by industry, US Special Operations, and US National Security veterans, Horizon3.ai is headquartered in San Francisco, CA, and made in the USA. | $250M / Series E / Aug 03, 2026 | |
Hyperlight
|
HyperLight provides thin-film lithium niobate photonic integrated circuit solutions. They deliver groundbreaking electro-optic and nonlinear optical solutions with scalable manufacturing processes. They work closely with their customers from conceptualization, design, prototyping, and transfer to volume production. | $80M / Series C / Jun 18, 2026 | |
Silicon Box
|
Silicon Box is an advanced OSAT (outsourced semiconductor assembly and testing) services provider, specializing in semiconductor integration. The company is capable of delivering full execution for semiconductor packaging, from initial design to final manufacturing of standard single chip packages to the most sophisticated chiplet-based systems,enabling applications that include AI (artificial intelligence), HPC (high performance computing), EV (electric vehicles), automotive, power management, mobile chipsets and processors, applications processors, radiofrequency, and more. | $155M / Series B / May 12, 2026 | |
Iterative Health
|
Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $77M / Series C / Apr 30, 2026 | |
Amity Corporation
|
The future is social — and Amity is on a mission to make social experiences more accessible than ever. Amity's technology powers digital communities, enabling users to connect with like-minded people and find a sense of belonging.Amity Social Cloud, the company’s flagship platform, allows developers to easily add plug-and-play socialfeatures to any app or digital platform. In a booming and crowded mobile app marketplace, this enables product and marketing teams to drive engagement, build communities, increase retention and grow revenues.Amity’s platform is used by more than 10 million people every month, powering in-app social experiences and social networks for hundreds of customers operating in many different industries, ranging from sport, media, retail, to banking and education. Notable clients include industry-leading enterprises such as AirAsia, True Corporation, and Unilever.Amity currently has over 200 employees spread across offices in Bangkok, London, Milan, and Miami. | $100M / Series D / Mar 25, 2026 | |
CesiumAstro
|
CesiumAstro delivers communication systems for satellites, UAVs, launch vehicles, and other space or airborne platforms. Each of the company's products combines carefully selected COTS components with the traditional reliability necessary for aerospace systems. Its products enable connectivity between satellites, drones, planes, cars, andother mobile devices and generate electronically steerable beams of radio waves carrying information between the devices, and its software stitches the information together. | $270M / Series C / Feb 02, 2026 | |
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M / Series D / Jan 28, 2026 | |
SCI Ecommerce
|
SCI Ecommerce Pte Ltd is the No. 1 E-commerce solution provider in Southeast Asia for local and overseas brands. | $31.9M / Jan 09, 2026 | |
Aether Fuels
|
Aether Fuels is a cutting-edge climate technology firm that seeks to use ground-breaking methods for creating scalable, affordable, and sustainable fuels to decarbonize "hard-to-abate" sectors including aviation and ocean shipping. | $15M / Convertible Note / Dec 30, 2025 | |
d-Matrix
|
D-Matrix is developing a platform that enables data centers to handle large-scale generative AI inference with high throughput and low latency. The company’s offering includes the Corsair™ inference accelerator card, the JetStream™ I/O networking accelerator, and the SquadRack™ rack-scale system, all designed to work together to deliverefficient inference compute. Their technology brings memory and compute closer together, embedding processing inside memory to reduce data movement, improve speed, and energy efficiency. The stack also includes software tools for deployment, model debugging, and performance monitoring, enabling enterprises to scale inference workloads across models and usage scenarios. | $275M / Series C / Nov 12, 2025 | |
| See all 195 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EDBI invest in?
EDBI invests primarily in Biotechnology, Software and Health Care startups, most often at Series C and Series B stage. Most of the 195 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EDBI's check size?
EDBI typically joins rounds of $20M–$170M at Series B, $12M–$275M at Series C and $17M–$400M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EDBI participates in.
How do I contact EDBI?
Public channels for EDBI include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EDBI?
The team at EDBI includes Chu Swee Yeok (CEO and President), Jolene Ooi (Senior Principal) and Lawrence Low (Senior Vice President, Investments). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
